{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:15:46Z","timestamp":1758636946107,"version":"3.41.2"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Prospective observations on the effectiveness, safety, tolerance, and influence of comorbidity of add-on lacosamide (LCM) therapy are still lacking, especially for domestic generic LCM in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>In this multicenter real-world study, we aimed to evaluate lacosamide (LCM) as the first add-on therapy in adult Chinese patients with focal epilepsy that had initially been treated with monotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cohort of consecutive focal epilepsy patients aged over 16 years were enrolled and followed at the multi-epilepsy centers in China. LCM was prescribed as the first add-on therapy. The main outcome measures included seizure frequency and response rate. Data on seizure-free rate, retention rate, scales of depression and anxiety, and adverse events were also collected as additional outcome measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total number of 107 adult subjects (60 men, 56.07%) were enrolled. The mean age was 37.16 \u00b1 15.01 years, and the mean age at seizure onset was 312.35 \u00b1 199.97 months. After the LCM add-on therapy, the \u226550% response rates were 76.19, 81.73, 94.12, and 95.79% at the visit at 4 weeks (visit 2), 8 weeks (visit 3), 16 weeks (visit 4), and 24 weeks (visit 5), respectively, compared to the baseline (visit 1). A total of 34 patients (31.78%) had no seizures during the whole follow-up period. The posttreatment emotional performance of the 97 subjects, defined as generalized anxiety disorder (GAD) and Neurological Disorders Depression Inventory (NDDI) scores, was significantly better than the baseline one. Only one patient suffered from mild dizziness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>LCM as the first add-on therapy in adult focal epilepsy in China was effective and safe. Further prospective studies with long-term follow-up periods are needed to confirm our present findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:ext-link>http:\/\/www.chictr.org.cn<\/jats:ext-link>, ChiCTR2100042485.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1136814","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T15:54:55Z","timestamp":1680796495000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Lacosamide as the first add-on therapy in adult patients with focal epilepsy: A multicenter real-world study"],"prefix":"10.3389","volume":"14","author":[{"given":"Wenyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xintong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Drug-resistant epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","article-title":"Development of new antiepileptic drugs: challenges, incentives, and recent advances","volume":"6","author":"Perucca","year":"2007","journal-title":"Lancet Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S1474-4422(20)30035-1","article-title":"30 years of second-generation antiseizure medications: impact and future perspectives","volume":"19","author":"Perucca","year":"2020","journal-title":"Lancet Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","article-title":"The consequences of refractory epilepsy and its treatment","volume":"37","author":"Laxer","year":"2014","journal-title":"Epilep Behav."},{"key":"B6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/seiz.2000.0442","article-title":"Epilepsy after the first drug fails: substitution or add-on?","volume":"9","author":"Kwan","year":"2000","journal-title":"Seizure."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1111\/epi.14565","article-title":"Response to treatment schedules after the first antiepileptic drug failed","volume":"59","author":"Chi","year":"2018","journal-title":"Epilepsia."},{"key":"B8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1474-4422(16)30292-7","article-title":"Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial","volume":"16","author":"Baulac","year":"2017","journal-title":"Lancet Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia."},{"key":"B10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1527-3458.2007.00001.x","article-title":"Lacosamide: a review of preclinical properties","volume":"13","author":"Beyreuther","year":"2007","journal-title":"CNS Drug Rev."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008841.pub2","article-title":"Lacosamide add-on therapy for partial epilepsy","author":"Weston","year":"2015","journal-title":"Cochr Database Syst Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2165\/11586830-000000000-00000","article-title":"Examining the clinical utility of lacosamide: pooled analyses of three phase II\/III clinical trials","volume":"24","author":"Chung","year":"2010","journal-title":"CNS Drugs."},{"key":"B13","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia."},{"key":"B14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1528-1167.2012.03589.x","article-title":"The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Zaccara","year":"2013","journal-title":"Epilepsia."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.09.005","article-title":"Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX)","volume":"83","author":"Bialer","year":"2009","journal-title":"Epilepsy Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1528-1167.2012.03407.x","article-title":"Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial","volume":"53","author":"Husain","year":"2012","journal-title":"Epilepsia."},{"key":"B17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.seizure.2015.04.003","article-title":"Long-term efficacy and safety of lacosamide monotherapy in the treatment of partial-onset seizures: a multicenter evaluation","volume":"29","author":"Gir\u00e1ldez","year":"2015","journal-title":"Seizure."},{"key":"B18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia."},{"key":"B19","first-page":"833","article-title":"Bioequivalence of lacosamide tablets in healthy volunteers with oral administration under fasting condition","volume":"7","author":"Kang","year":"2019","journal-title":"Chin J New Drugs."},{"key":"B20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/epi4.12554","article-title":"The National Comprehensive Governance for epilepsy prevention and control in China","volume":"7","author":"Li","year":"2022","journal-title":"Epilepsia Open."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1212\/01.WNL.0000059867.35547.DE","article-title":"The prevalence and treatment gap in epilepsy in China: an ILAE\/IBE\/WHO study","volume":"60","author":"Wang","year":"2003","journal-title":"Neurology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.yebeh.2018.07.019","article-title":"Comparative effectiveness of add-on therapy with newer-generation antiepileptic drugs in Bulgarian patients with refractory epilepsy","volume":"87","author":"Viteva","year":"2018","journal-title":"Epilep Behav."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/epi.16597","article-title":"A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs-From phenobarbital to cenobamate and beyond","volume":"61","author":"Odi","year":"2020","journal-title":"Epilepsia."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure medications for adults with epilepsy: a review","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA."},{"key":"B25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.eplepsyres.2010.10.006","article-title":"Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population","volume":"92","author":"An","year":"2010","journal-title":"Epilepsy Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1471-2377-13-75","article-title":"The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a northern Han Chinese population","volume":"13","author":"Lv","year":"2013","journal-title":"BMC Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.yebeh.2014.05.025","article-title":"Genetic predictors of Stevens-Johnson syndrome and toxic epidermal necrolysis induced by aromatic antiepileptic drugs among the Chinese Han population","volume":"37","author":"Wang","year":"2014","journal-title":"Epilepsy Behav."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia."},{"key":"B29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/0883073812462887","article-title":"Efficacy of lacosamide as adjunctive therapy in children with refractory epilepsy","volume":"29","author":"Yorns","year":"2014","journal-title":"J Child Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/jpc.12850","article-title":"Lacosamide as adjunctive therapy in treatment-resistant epilepsy in childhood","volume":"51","author":"Gulati","year":"2015","journal-title":"J Paediatr Child Health."},{"key":"B31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.yebeh.2013.07.024","article-title":"Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide","volume":"29","author":"Villanueva","year":"2013","journal-title":"Epilepsy Behav."},{"key":"B32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.yebeh.2013.11.016","article-title":"Prospective audits with newer antiepileptic drugs in focal epilepsy: insights into population responses?","volume":"31","author":"Brodie","year":"2014","journal-title":"Epilepsy Behav."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1111\/epi.13224","article-title":"A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: the VITOBA study","volume":"56","author":"Runge","year":"2015","journal-title":"Epilepsia."},{"key":"B34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.seizure.2015.07.001","article-title":"Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: a multicentre open-label trial","volume":"31","author":"Zadeh","year":"2015","journal-title":"Seizure."},{"key":"B35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.yebeh.2015.03.012","article-title":"Validation of the chinese version of the neurological disorders depression inventory for epilepsy (C-NDDI-E) in West China","volume":"47","author":"Tong","year":"2015","journal-title":"Epilepsy Behav."},{"key":"B36","doi-asserted-by":"publisher","first-page":"106265","DOI":"10.1016\/j.eplepsyres.2020.106265","article-title":"Effects of seizure frequency, depression and generalized anxiety on suicidal tendency in people with epilepsy","volume":"160","author":"Liu","year":"2020","journal-title":"Epilepsy Res."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1136814\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T15:54:57Z","timestamp":1680796497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1136814\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":36,"alternative-id":["10.3389\/fneur.2023.1136814"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1136814","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2023,4,6]]},"article-number":"1136814"}}